Actively Recruiting
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
Led by Tang-Du Hospital · Updated on 2024-05-30
40
Participants Needed
1
Research Sites
68 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
CONDITIONS
Official Title
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 40 to 80 years
- Histologically confirmed lung squamous cell carcinoma with operable locally advanced stage
- No prior anti-tumor therapy
- Received neoadjuvant immunotherapy consisting of three cycles of anti-PD-1 immune checkpoint blockade plus nab-paclitaxel and carboplatin
- Availability of pre-treatment tissue samples
You will not qualify if you...
- Presence of central nervous system metastases
- Presence of immunodeficiency disease or use of immunosuppressants within 14 days before starting study treatment
- Uncontrolled hypertension
- History of or current pulmonary fibrosis or interstitial lung disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hongtao Duan
Xi’an, Shanxi, China, 710038
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here